Ambu's first-half profit hit by lawsuit:
This article was originally published in Clinica
Ambu (Denmark) has reported six-month profits "somewhat below the planned level" because of an unforeseen DKr 5 million ($0.9 million) cost connected with the settlement of a US lawsuit on patent rights. Net income halved to DKr 4.6 million from DKr 10.1 million a year earlier despite sales increasing 3% to DKr 109 million. In Europe, turnover rose 15%, the company says. Ambu has lowered its full-year forecast to DKr 13-14 million against last year's DKr 16.3 million.
You may also be interested in...
Dr Reddy's is poised to expand its OTC offering in Russia and certain CIS countries by snapping up a basket of allergy brands from fellow Indian firm Glenmark.
Sandoz has launched an awareness campaign under the banner of “Ask For Generics” in the US. The initiative is aiming to educate stakeholders on the benefits of generics and their quality, safety and efficacy.
European Commission proposals for strengthening intellectual property protections in the EU, particularly the supplementary protection certificate (SPC) system, have been broadly welcomed by Europe’s brand industry. But the medical NGO, MSF, says the SPC proposals run counter to the commission’s own efforts to improve access to medicines.